Company intelligence / Profile preview

北京厚成医药科技

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Houcheng Pharmaceutical Technology is a clinical-stage biotechnology company specializing in the discovery and development of protein degradation therapies. Established in 2018, the company utilizes its proprietary PROTAC and molecular glue platforms to create novel small molecule drugs for oncology and autoimmune disorders. Its lead program, HC-1101, is a next-generation BTK degrader designed to overcome resistance in B-cell malignancies. Houcheng Pharma is supported by prominent Chinese venture capital firms and maintains a focus on addressing high-unmet medical needs through targeted protein degradation.

Therapeutic areas: ImmunologyHematologyOncology
Modalities: Small moleculeProteolysis-targeting chimera therapyMolecular glue therapy
Industry: Biotech

Beyond the preview

Go deeper on 北京厚成医药科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 北京厚成医药科技.

Explore the full profile